Aventura, FL (February 20, 2020) – Biorasi, LLC and its Board of Directors are proud to announce the appointment of Chris O’Brien to the position of Chief Executive Officer (CEO). O’Brien will assume day-to-day leadership of Company operations, working closely with the Biorasi leadership team to deliver cutting-edge solutions for clinical research project management.
Boris Reznik, Ph.D., Founder and Board Chairman at Biorasi, has been serving as acting CEO and will be working closely with O’Brien to ensure the seamless transition of CEO responsibilities. Reznik will return to his current position as Board Chairman, continuing to play a key role in Biorasi’s business development activities and strategies for growth.
“We very excited to welcome Chris to Biorasi as our new CEO,” said Reznik. “We are deeply impressed with his breadth of business experience, his focus on team building and communication, and his strong understanding of our culture and core values. The Board of Directors and I are confident that Chris is the right leader to guide Biorasi’s present and future success. This was an extremely important decision for all of us here at Biorasi, and we are excited to have found such a great person to lead our company in effective growth and innovation.”
Chief Executive Officer at Biorasi
In his new role, O’Brien brings with him over 20 years of experience in leading high-performing teams as well as a strong track record of driving significant business results. Prior to joining Biorasi, O’Brien served as President and COO of Decision Resources Group, a global company engaged in supporting the pharmacology and biotech industries in understanding market trends and enhancing commercial execution for medical treatments. He has also served as COO at The Kessler Group, a financial services company specializing in partnership development, and is the Founder of independent advisory practice Linchpin Partnerships.
O’Brien received his MBA from The Amos Tuck School of Business Administration at Dartmouth College. He received his B.A., magna cum laude, in English Studies from Middlebury College and was a Member of Phi Beta Kappa.
“I am delighted to join this extraordinary team at Biorasi,” said O’Brien. “Sponsors entrust their most vital intellectual property to CROs to demonstrate value. We take our responsibilities seriously and believe we can deliver breakthrough value for our partners.”
To learn more about Chris O’Brien and the mission and vision of Biorasi, please visit www.biorasi.com or contact us at firstname.lastname@example.org or (786) 388-0700.
Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Pharmaceutical companies around the globe rely on Biorasi to consistently deliver success in clinical trial programs for rare and orphan disease and other hard to recruit patient populations such as precision medicine, as well as successful clinical trial rescue. Biorasi’s expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.
Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. The company has received the coveted CRO Leadership Award from Life Science Leader magazine and has been placed on the INC 500 list of fastest-growing companies in America.